Oxytocin intranasal - Teijin Pharma
Alternative Names: TTA-121Latest Information Update: 28 Nov 2024
At a glance
- Originator Teijin Pharma
- Class Amides; Amines; Analgesics; Antihaemorrhagics; Antihyperglycaemics; Antimigraines; Behavioural disorder therapies; Hormones; Macrocyclic lactams; Obesity therapies; Oxytocics; Pyrrolidines
- Mechanism of Action Oxytocin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Fibromyalgia; Pain
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for preclinical development in Pain in Japan
- 28 Dec 2023 No recent reports of development identified for preclinical development in Fibromyalgia in Japan (Intranasal)
- 11 Oct 2020 Preclinical trials in Pain in Japan (unspecified route)